OVID News and Press, Ovid Therapeutics Inc. From 07/02/19

NEW YORK, July 02, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that the European Commission (EC) has granted orphan drug desi...

Gainers:  Infrastructure and Energy Alternatives (NASDAQ: IEA ) +47% . SSLJ.com (YGTY) +23% . Emmis Communications Corporation (NASDAQ: EMMS ) +24% . Pioneer Power Solutions (NASDAQ: PPSI ) +17% . Seadrill (NYSE: SDRL ) +17% . Ovid Therapeutics (NASDAQ: OVID ) +15% . NeoPhotonic...

Phase 3 NEPTUNE Trial of OV101 Expected to Enroll the First Patients in the Third Quarter of 2019; CGI-I Angelman Syndrome Scale will be the Sole Primary Endpoint Ovid to Review NEPTUNE Trial Details and Additional Pipeline Program Highlights at Today’s R&D Day to be held...

NEW YORK, June 18, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological disorders, today announced that it will host an R&D Day on Thursday, June 27, 2019 f...

Quick Take Stoke Therapeutics ( STOK ) has filed to raise gross proceeds of $100 million from a U.S. IPO, according to an S-1 registration statement . The firm is developing therapeutics for severe genetic diseases with a focus on dominant loss-of-function [haploinsufficient] diseases of ...

NEW YORK , May 23, 2019 /PRNewswire/ -- Ovid Therapeutics Inc. (NASDAQ: OVID ), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, will present data on safety, tolerability, exploratory and secondary outcomes ...

Ovid Therapeutics ( OVID ) has certainly been a poor performer, with shares having fallen by 87% since its IPO priced at $15 in 2017. While the stock initially produced a 75% run up gain since my initial article, it's fallen by more than 80% since my November 2017 update piece. The comp...

Catalyst Pharmaceuticals (NASDAQ: CPRX )  -39%  after FDA OKs Firdapse competitor. More news on: Catalyst Pharmaceuticals, Inc., Intersect ENT, Inc., TherapeuticsMD, Inc., Stocks on the move, Read more ...

Ovid Therapeutics (NASDAQ: OVID ): Q1 GAAP EPS of -$0.46 misses by $0.05. More news on: Ovid Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Remains on track for all previously stated milestones expected throughout 2019 The STARS study selected as one of three abstracts featured at the 2019 AAN Top Science Press Conference NEW YORK, May 07, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceuti...